Escalier Biosciences BV, a Nijmegen, The Netherlands-based biopharmaceutical company, raised $19m in Series B financing.
The round was led by Forbion with participation from existing investors New Science Ventures and BioGeneration Ventures. In conjunction with the funding, Marco Boorsma, General Partner at Forbion, will join Escalier’s Board of Directors.
The company intends to use the funds to advance its RORγt compounds through human proof-of-concept studies.
Led by Raju Mohan, Ph.D., Chief Executive Officer, Escalier Biosciences is developing both oral and topical RORγt drug candidates for psoriasis and other autoimmune diseases. The nuclear hormone receptor RORγt has emerged as the “master” regulator of Th17 cell differentiation and the production of pro-inflammatory cytokines, such as IL-17A and IL-17F. Increased production of these cytokines has been linked to the pathophysiology of psoriasis. Small molecule inhibitors of RORγt have been shown to reduce production of IL-17 in immune cells and are promising therapies for psoriasis and other autoimmune conditions.
The company expects its topical compound to enter the clinic in mid-2018.
Escalier also has offices in Encinitas, California.